Zentiva accepts higher Sanofi takeover offer
Czech generics drugs maker Zentiva has accepted a higher takeover offer from French drugmaker Sanofi-Aventis that values Zentiva at around €1.8 billion, Sanofi said.
Sanofi said it had raised its offer to 1,150 Czech crowns ($69.32) per share. This represents a premium of around 6% to Zentiva's closing share price of 1,085 crowns on Friday. Zentiva had rejected an earlier bid by Sanofi.
Sanofi's planned acquisition of Zentiva takes it deeper into the field of generic drug production, an area which has previously been shunned by large pharmaceutical companies but is now receiving increased interest as a way to tap booming emerging markets.
Sanofi shares closed at €47.56 on Friday, giving the company a market capitalization of around €62.5 billion. Sanofi shares have fallen around 24% since the start of the year, in line with a similar decline in France's benchmark CAC-40 index. (Reuters)
ADVERTISEMENT
Hungary Cattle Stock Edges Down 2% in a Year
Parliament Negates Mandatory Membership in MOK
Regional Cloud Sales Growth Expected in Coming Years
Meet the Expat CEO of the Year Nominees
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
